Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

In addition to this, Moody’s upgraded Merck & Co., Inc.’s senior unsecured revolving credit facility to Aa3 from A1, and the senior unsecured shelf ratings of both Merck & Co., Inc. and MSD ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

A class action lawsuit is brewing against Merck & Co. over claims of securities fraud, and investors aren’t exactly raising a ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") and reminds investors of the April 14, 2025 ...